Changing the future of intestinal failure in intestinal chronic inflammation: towards innovative predictive factors and therapeutic targets.

Short bowel syndrome (SBS) is a malabsorptive condition mostly caused by massive surgical resection of the small intestine and is associated with significant morbidity and mortality, reduced quality of life, and high healthcare costs. Inflammatory bowel disease (IBD), specifically Crohn's disease represent a potential cause leading to an increased risk of SBS with huge clinical consequences. Currently, there are no biomarkers indicating a higher risk to develop SBS or intestinal deficiency in IBD and the therapeutic strategies represents an unmet need for this chronic debilitating disorder. The overall goal of this application is the development of new preventive and therapeutic strategies for IBD patients with SBS and intestinal deficiency. The project will proceed with two parallel studies aiming to develop prevention strategies for patients at high risk of SBS development and innovative treatments for consolidated SBS.